Success story

The Challenge

A leading global pharmaceutical company was struggling to keep up with the need to verify informed consent for secondary research due to manual and inefficient processes.

Validating proper consent for existing bio samples in their various CTMS databases was difficult to determine and impacted the ability to initiate new research. In this legacy approach, once target samples were identified, the sample IDs were transferred to Excel for manual tracking and approvals.

They would examine consent forms using patient IDs to refer to the source document repository. Once consent was confirmed, the research team would then engage the ethics team for validation and approval. The process to obtain a sufficient quantity of authorized samples to start the research process could take months.

The solution

Virtusa implemented the case-based SCORE Consent digital process automation application and integrated the system into the company’s various CTMS databases to source initial sample targets.

Once a target list of representative samples is identified, SCORE Consent automatically queries the content repository mapping the patient ID to archived consent forms. The document-based forms are then processed by applying artificial intelligence and natural language processing algorithms to extract the consent purpose and level within the documents.

High probability records are shared with the R&D coordinator to validate intent. After pairing with the designated sample targets, the combination of sample ID and patient consent are then shared with the ethics team for final validation.

Results

By combining best-of-breed digital process automation technology, the entire process can now be completed in a fraction of the time it took to perform the same process manually, speeding bio samples to R&D for new drug development.

Services

Industries

Insights

Careers

About